What should be the primary target of "treat to target" in psoriatic arthritis?
<h4>Background</h4> <p>Treat to Target in psoriatic arthritis (PsA) recommendations have stated that the target should be remission or inactive disease. Potential definitions include Very Low Disease Activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Act...
Auteurs principaux: | Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
Journal of Rheumatology
2018
|
Documents similaires
-
What should be the primary target of ‘treat to target’ in PsA?
par: Coates, L, et autres
Publié: (2018) -
Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
par: Coates, L, et autres
Publié: (2022) -
Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
par: Coates, L, et autres
Publié: (2019) -
Sustained very low disease activity and remission in psoriatic arthritis patients
par: Lubrano, E, et autres
Publié: (2019) -
New approved drugs for psoriatic arthritis
par: F.M. Perrotta, et autres
Publié: (2016-09-01)